Elevated concentrations of syndecan-1 and HGF in the bone marrow of patients with myeloma.

Serum or plasma from bone marrow aspirates of 35 patients with newly diagnosed multiple myeloma (MM), 21 controls with other diseases, and 14 healthy controls were analyzed by ELISA for syndecan-1 (A). Median levels are indicated by the horizontal bars. The difference between patients with myeloma and patient controls was highly significant (P = .002). The difference between patients with myeloma and healthy controls was highly significant (P = .001). (B) HGF. Median levels are indicated by the horizontal bars. The difference between patients with myeloma and patient controls was highly significant (P = .004). The difference between patients with myeloma and healthy controls was also significant (P = .01).